Diabetes start-up brings in cash and a partner
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Finance Watch: Semma Raises $114m As VC Funding Keeps Up Brisk Pace
Semma closed a $114m Series B round to fund development of insulin-producing cells. Also, Tesaro and Catalyst are among recent public company financings, while Otonomy shifted gears, laying off sales staff.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.